Research programme: tyrosine phosphatase inhibitors - Molecumetics
Latest Information Update: 14 Mar 2008
At a glance
- Originator Molecumetics
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 30 Nov 2002 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 20 Apr 2001 Preclinical development for Diabetes mellitus in USA (Unknown route)